Guru Sonpavde, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses the effects of angiotensin blockade on the response to PD-1/L1 inhibitor treatment in patients with metastatic urothelial carcinoma. Using datasets from Dana-Farber Cancer Institute (n=178) and Moffitt Cancer Center (n=101), results from multivariate analyses demonstrated robust associations between ACE or ARB inhibitor use with PD-1/L1 inhibition for tumor regression.
